statistiche ricercatore

COSCIA, MARTA

Distribuzione geografica

Continente	#
NA - Nord America	6.015
AS - Asia	3.881
EU - Europa	1.491
SA - Sud America	516
Continente sconosciuto - Info sul continente non disponibili	243
AF - Africa	95
OC - Oceania	10
Totale	12.251

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	5.801
SG - Singapore	1.831
CN - Cina	681
HK - Hong Kong	620
BR - Brasile	431
IT - Italia	354
VN - Vietnam	323
GB - Regno Unito	270
FR - Francia	235
RU - Federazione Russa	233
BD - Bangladesh	155
FI - Finlandia	110
DE - Germania	96
MX - Messico	91
CA - Canada	79
IN - India	71
NG - Nigeria	38
IQ - Iraq	32
TR - Turchia	30
NL - Olanda	29
ZA - Sudafrica	28
SE - Svezia	26
AR - Argentina	25
JP - Giappone	24
AT - Austria	22
ES - Italia	22
PL - Polonia	20
SA - Arabia Saudita	17
CO - Colombia	14
LT - Lituania	14
VE - Venezuela	14
IE - Irlanda	13
PK - Pakistan	13
ID - Indonesia	11
JM - Giamaica	11
UA - Ucraina	11
UZ - Uzbekistan	11
EC - Ecuador	10
MY - Malesia	10
AU - Australia	9
MD - Moldavia	9
CR - Costa Rica	8
NP - Nepal	8
CH - Svizzera	7
CL - Cile	7
HN - Honduras	7
KE - Kenya	7
AE - Emirati Arabi Uniti	6
JO - Giordania	6
EE - Estonia	5
EG - Egitto	5
PH - Filippine	5
GT - Guatemala	4
MA - Marocco	4
TN - Tunisia	4
TT - Trinidad e Tobago	4
BE - Belgio	3
BO - Bolivia	3
CZ - Repubblica Ceca	3
IR - Iran	3
PE - Perù	3
PS - Palestinian Territory	3
PY - Paraguay	3
BB - Barbados	2
BG - Bulgaria	2
CY - Cipro	2
DZ - Algeria	2
ET - Etiopia	2
GR - Grecia	2
GY - Guiana	2
IL - Israele	2
KG - Kirghizistan	2
KR - Corea	2
LB - Libano	2
NI - Nicaragua	2
OM - Oman	2
SR - Suriname	2
SV - El Salvador	2
UY - Uruguay	2
AM - Armenia	1
BH - Bahrain	1
BS - Bahamas	1
CI - Costa d'Avorio	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
HU - Ungheria	1
KH - Cambogia	1
KN - Saint Kitts e Nevis	1
KZ - Kazakistan	1
LK - Sri Lanka	1
LV - Lettonia	1
LY - Libia	1
MT - Malta	1
NZ - Nuova Zelanda	1
PR - Porto Rico	1
PT - Portogallo	1
QA - Qatar	1
SN - Senegal	1
SY - Repubblica araba siriana	1
TG - Togo	1
Totale	12.005

Salva come PNG Salva come JPEG

Città	#
San Jose	1.623
Singapore	1.015
Hong Kong	610
Ashburn	597
Chicago	479
Council Bluffs	433
Dallas	387
The Dalles	253
Boardman	236
Beijing	211
Lauterbourg	196
London	190
Santa Clara	124
Ho Chi Minh City	120
Los Angeles	117
New York	102
Helsinki	94
Hanoi	80
Orem	75
Mexico City	69
São Paulo	48
Brooklyn	45
San Francisco	41
Abuja	38
Denver	37
Atlanta	35
Houston	29
Munich	28
Nuremberg	27
Assago	26
Chennai	26
Manchester	26
Milan	26
Rome	26
Phoenix	23
Tokyo	23
Frankfurt am Main	22
Montreal	22
Johannesburg	21
Toronto	21
Stockholm	20
Da Nang	19
Boston	18
Warsaw	18
Guangzhou	16
Poplar	16
Salt Lake City	16
Shanghai	16
Haiphong	15
Ankara	14
Seattle	14
Turku	14
Baghdad	13
Buffalo	13
Dublin	13
Shenzhen	13
Rio de Janeiro	12
Amsterdam	11
Belo Horizonte	11
Hangzhou	11
Tashkent	11
Tianjin	11
Porto Alegre	10
Elk Grove Village	9
Flanders	9
Vergiate	9
Calgary	8
Chandler	8
Charlotte	8
Düsseldorf	8
Moscow	8
Riyadh	8
San José	8
Secaucus	8
Vienna	8
Honolulu	7
Miami	7
Nairobi	7
New Delhi	7
Oklahoma City	7
Zhengzhou	7
Amman	6
Cavaria con Premezzo	6
Contagem	6
Detroit	6
Fairfield	6
Fort Worth	6
Fortaleza	6
Indianapolis	6
Jacksonville	6
Juneau	6
Kathmandu	6
Kingston	6
Naples	6
Ottawa	6
Piracicaba	6
Romola	6
Salvador	6
Staten Island	6
São José dos Campos	6
Totale	8.181

Salva come PNG Salva come JPEG

Nome	#
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs	599
AISF position paper on HCV in immunocompromised patients	155
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY	89
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL)	86
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia	82
Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study	79
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma	78
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: a retrospective real‐life multicenter Italian cohort	77
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway	76
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia	72
B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide	72
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study	72
Autoimmune hemolytic anemia during bendamustine plus rituximab treatment in CLL patients: multicenter experience	72
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs	71
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia	71
Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells	71
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: A GIMEMA, ERIC and UK CLL FORUM study	69
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS	68
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study	68
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment	68
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS	68
Regulation of HIF-1α in TP53 disrupted chronic lymphocytic leukemia cells and its potential role as a therapeutic target	68
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials	67
Immune dysfunctions and immune-based therapeutic interventions in chronic lymphocytic leukemia	67
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation	66
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study	66
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy	66
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS	65
BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib	65
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification	65
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment	65
Treatment of chronic lymphocytic leukemia in the new drugs era: the state of art in the Italian landscape	64
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials	63
HLA-G is a component of the CLL escape repertoire to generate immune suppression: impact of HLA-G 14 bp (rs66554220) polymorphism	63
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia	63
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide	62
MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY)	62
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives	62
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL)	62
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia	62
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice	61
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study	61
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA	60
A PHASE II MULTI-CENTER TRIAL OF PENTOSTATIN PLUS CYCLOPHOSPHAMIDE WITH OFATUMUMAB (PCO) IN OLDER PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS	60
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	59
Immunotherapeutic strategies in chronic lymphocytic leukemia: advances and challenges	59
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene	59
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino	58
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status	57
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study	56
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells	56
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study	56
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells	55
Mutations in NOTCH1 PEST Domain Orchestrate CCL19-Driven Homing of Chronic Lymphocytic Leukemia (CLL) Cells By Modulating the Gene DUSP22	55
Effective anti-tumor immunomodulatory properties of zoledronic acid	55
The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy	55
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome	54
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus	54
LDH Levels Predict Progression-Free Survival in Treatment-NaIVe Patients with Trisomy 12 Chronic Lymphocytic Leukemia	54
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA	54
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PRELIMINARY REPORT OF THE ITALIAN TRIAL	54
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL	53
Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia	53
Chlorambucil PLUS Rituximab As FRONT-LINE Therapy for Elderly and/or Unfit CLL Patients. LONG-TERM Follow-up and Correlation with Biologic-Based Risk Stratification	53
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis	53
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation	53
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells	53
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study	52
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia	52
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA)	52
Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells	52
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status	52
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells	52
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients	51
TARGETING HIF-1 AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER TUMOR-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	51
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia	51
Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study	51
Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside	51
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia	51
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications	51
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up	51
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia	51
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET	51
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells	51
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs	51
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients	51
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL	51
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF)	50
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells	50
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia	50
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence	50
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial	50
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA	50
Bendamustine and Alemtuzumab combination in relapsed and refractory chronic lymphocytic leukemia: interim report of the italian trial	49
FIRST-LINE TREATMENT CHOICE FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: WHAT DO CLINICIANS CARE ABOUT? THE CLL FITNESS STUDY	49
High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study	49
NEW PROSPECTS FOR INDUCTION OF ANTI-LYMPHOMA IMMUNITY USING DNA VACCINES EXPRESSING CHEMOKINE-PARTICLES	49
Real life use of bendamustine in elderly patients with lymphoid neoplasia	49
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy	49
LDH AS PREDICTIVE PARAMETER IN TREATMENT-NAIVE PATIENTS WITH TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA	49
Totale	6.565

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	61.926
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	61.926

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	7	0	0	2	0	0	0	0	1	1	1	1	1
2022/2023	23	2	1	3	1	3	3	0	3	5	0	0	2
2023/2024	27	4	5	5	5	6	0	0	1	0	0	0	1
2024/2025	3.434	239	34	868	158	181	118	136	111	283	200	222	884
2025/2026	8.412	411	465	436	846	458	399	2.377	348	788	536	945	403
2026/2027	315	245	70	0	0	0	0	0	0	0	0	0	0
Totale													12.251